The National Committee of the Chinese People's Political Consultative Conference (CPPCC), the country's top political advisory body, held a press conference on Wednesday afternoon, ahead of the top political advisory body's annual session.
Guo Weimin, spokesperson for the third session of the 13th CPPCC National Committee, briefed the media on the session and took questions through video conference due to COVID-19 pandemic response.
The CPPCC will open its session on March 4 at 3:00 p.m. and conclude on March 10, Guo said.
Amid regular measures to prevent and control COVID-19, this year's session will be shorter than previously planned.
"Last year, we shortened duration, streamlined staffing and streamlined documents. We also combined physical meetings with virtual ones. This year, we will build on past practices and make the program more effective," Guo said.
The upcoming session will discuss the draft plan for the 14th Five-Year Plan and other key political and economic topics.
Safety, efficacy of COVID-19 vaccine
The claim that China exports COVID-19 vaccines to expand geopolitical clout is narrow-minded, Guo told the press conference.
China has always put the safety and efficacy of COVID-19 vaccines first, Guo said. Ever since the COVID-19 pandemic struck, China has made vaccine research and development as one of its major tasks, and enormous resources have been poured into vaccine development.
As of February 28, China has administered 52 million vaccine doses. Some foreign leaders have taken Chinese vaccines as well, he said.
China has also provided vaccines to 69 countries and two international organizations, and exported vaccines to 28 countries, Guo said.